Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Frank van Leth^{1

2}, Gunar Günther^{3

4

5}, Harald Hoffmann^{6

7}, Christoph Lange^{3

4

8

9}; European MDR-TB Database Collaboration

Collaborators, Affiliations

Collaborators

European MDR-TB Database Collaboration:
Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Mathilde Fréchet-Jachym, Gina Gualano, Lorenzo Guglielmetti, Gunar Günther, Harald Hoffmann, Jan Heyckendorf, Barbara Kalsdorf, Heinke Kunst, Christoph Lange, Wiel de Lange, Damien Le Dû, Vaira Leimane, Frank van Leth, Rita Macedo, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Ioana D Olaru, Olena Oliveira, Veronika Polcová, Emanuele Pontali, Cristina Popa, Jérôme Robert, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Nicolas Veziris, Piret Viiklepp

Affiliations

¹ 1 University of Amsterdam Amsterdam, the Netherlands.
² 2 Amsterdam Institute for Global Health and Development Amsterdam, the Netherlands.
³ 3 Research Center Borstel Borstel, Germany.
⁴ 4 German Center for Infection Research (DZIF) Borstel, Germany.
⁵ 5 University of Namibia, School of Medicine Windhoek, Namibia.
⁶ 6 SYNLAB Gauting, SYNLAB Humane Genetic Munich-Gauting, Germany.
⁷ 7 Institute of Microbiology & Laboratory Medicine, Dpt IML red; WHO Supranational Reference Laboratory of Tuberculosis Munich-Gauting, Germany.
⁸ 8 University of Lübeck Lübeck, Germany and.
⁹ 9 Karolinska Institute Stockholm, Sweden.

PMID: 28715229
DOI: 10.1164/rccm.201705-0995LE

Comment

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Frank van Leth et al. Am J Respir Crit Care Med. 2017.

. 2017 Dec 1;196(11):1489-1490.

doi: 10.1164/rccm.201705-0995LE.

Authors

Frank van Leth^{1

2}, Gunar Günther^{3

4

5}, Harald Hoffmann^{6

7}, Christoph Lange^{3

4

8

9}; European MDR-TB Database Collaboration

Collaborators

European MDR-TB Database Collaboration:
Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Mathilde Fréchet-Jachym, Gina Gualano, Lorenzo Guglielmetti, Gunar Günther, Harald Hoffmann, Jan Heyckendorf, Barbara Kalsdorf, Heinke Kunst, Christoph Lange, Wiel de Lange, Damien Le Dû, Vaira Leimane, Frank van Leth, Rita Macedo, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Ioana D Olaru, Olena Oliveira, Veronika Polcová, Emanuele Pontali, Cristina Popa, Jérôme Robert, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Nicolas Veziris, Piret Viiklepp

Affiliations

¹ 1 University of Amsterdam Amsterdam, the Netherlands.
² 2 Amsterdam Institute for Global Health and Development Amsterdam, the Netherlands.
³ 3 Research Center Borstel Borstel, Germany.
⁴ 4 German Center for Infection Research (DZIF) Borstel, Germany.
⁵ 5 University of Namibia, School of Medicine Windhoek, Namibia.
⁶ 6 SYNLAB Gauting, SYNLAB Humane Genetic Munich-Gauting, Germany.
⁷ 7 Institute of Microbiology & Laboratory Medicine, Dpt IML red; WHO Supranational Reference Laboratory of Tuberculosis Munich-Gauting, Germany.
⁸ 8 University of Lübeck Lübeck, Germany and.
⁹ 9 Karolinska Institute Stockholm, Sweden.

PMID: 28715229
DOI: 10.1164/rccm.201705-0995LE

No abstract available

PubMed Disclaimer

Comment on

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB database collaboration *. Lange C, et al. Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE. Am J Respir Crit Care Med. 2016. PMID: 27685538 No abstract available.
Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
Barry PM, Lowenthal P, True L, Henry L, Schack G, Wendorf K, Flood J, Shah N. Barry PM, et al. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. Am J Respir Crit Care Med. 2017. PMID: 28665681 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Collaborators

Affiliations

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Authors

Collaborators

Affiliations

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources